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Autoimmune pancreatitis is part of the spectrum of IgG4-associated diseases. Its diagnostic criteria and histological subtypes
have been formally proposed recently and although based on current data it has been suggested that there are diﬀerences in clinical
presentationamongpopulations,moreresearchisneededtoproperlyestablishifthisheterogeneityexists.Inthispaper,wedescribe
15 cases of autoimmune pancreatitis diagnosed at a Mexican centre of reference, all of them associated to the lymphoplasmocytic
sclerosing pancreatitis variant. The mean age at the onset of symptoms was 47.5 ± 14.4 years, and 53% of patients were male. The
main manifestations were weight loss (87%), obstructive jaundice (53%), and acute (27%) and chronic (27%) pancreatitis. Only
20% of patients had high IgG4 serum levels at the time of diagnosis. All patients receiving prednisone responded favourably, both
intheirpancreaticandextrapancreaticmanifestations.ClinicalmanifestationsofMexicanpatientsshowedcertaindiﬀerenceswith
respect to those usually reported.
1.Introduction
Autoimmune pancreatitis has travelled a relatively short way
from its ﬁrst description by Sarles et al. in 1961 [1] to the
formal suggestion of the very concept of autoimmune pan-
creatitis by Yoshida et al. in 1995 [2], and its subsequent
inclusion in a new group of diseases with systemic involve-
ment associated with an increase in serum IgG4 levels, after
the depiction by Kamisawa et al. [3].
Most descriptions have, up to now, been done on Asian
patients, even though there have been descriptions of pa-
tients in other geographical areas [4, 5].
In spite of the scant information available, mainly due to
the few reported cases of the disease and its aforementioned
“short” history, it is possible to assert that there are some
diﬀerences in the clinical presentation of patients of dif-
ferent ethnicities. In conjunction with the scarcity of avail-
able information, there is the added problem that until
recently, there is a lack of universally recognised criteria for
the diagnosis of the disease. Asian, European, and North
American consensus have so far been published [6–8]a n d
mostcentersusedistinctcriteria,makingdiﬃculttoestablish
comparison among patients in whom the diagnosis was2 ISRN Rheumatology
made at diﬀerent geographical areas. Recently, an interna-
tional panel of experts met to develop the International Con-
sensus Diagnostic Criteria for Autoimmune Pancreatitis to
favor the worldwide recognition of the illness [9].
Inthisconsensus,emphasisisplacedontheadvantagesof
classifying autoimmune pancreatitis into either of two types:
lymphoplasmocytic sclerosing pancreatitis (LPSP) and idio-
pathic duct-centric pancreatitis (IDCP), since it has been so
far ascertained that there are signiﬁcant variations in clinical
presentation, depending on the histological characteristics of
the pancreatitis under study [10].
For this reason, it is important to obtain clinical descrip-
tions of the disease, together with its histopathological char-
acteristics, as this will allow us to lay the foundations for
our understanding of the disease behaviour. The aim of this
study is to identify and describe the general characteristics of
patients diagnosed with autoimmune pancreatitis at a third-
level hospital in Mexico.
2. Patientsand Methods
From our hospital records, we identiﬁed 15 patients who
met the histological criteria for autoimmune pancreatitis.
All patients, but one, were Mexican Mestizos. A Mexican
Mestizo is deﬁned as an individual who was born in Mexico
and is a descendant from the native inhabitants of such re-
gion, and from individuals, mainly Spaniards of white or
African origin, or both, who came to America during the
16th century. The other patient was a Colombian.
Laboratory, radiologic, and clinical features were ob-
tained from clinical ﬁles.
Total IgG and IgG4 levels were measured by nephelome-
try. The cut-oﬀ was 1868mg/dL and 135mg/dL, respectively.
2.1. Pancreatic Histology and Immunostaining. Pancreatic
and extrapancreatic specimens were assessed by two pathol-
ogists. Morphological features on light microscopy were
described. Immunohistochemical staining for IgG4 was
performed in all cases and was considered positive with >10
IgG4-positive plasma cells per high power ﬁeld (HPF). Sub-
type classiﬁcation as either lymphoplasmocytic sclerosing
pancreatitis (LPSP) or idiopathic duct centric pancreatitis
(IDCP) was performed according to the 2011 International
Consensus Diagnostic Criteria for Autoimmune Pancreatitis
[9].
2.2. Imaging. Available pretreatment computed tomography
(CT) scans (n = 13) were reviewed by a single radiologist,
while in 2 patients only written radiological reports were at
hand. Pancreatic enlargement was deﬁned as an increase in
size of the gland in the absence of a discrete mass. Mass was
deﬁned as a lesion that had diﬀerent density compared with
surrounding pancreatic tissue. Pancreatic duct patency was
assessed and extrapancreatic lesions were recorded.
2.3. Response to Steroid Therapy. Biliary and pancreatic duct
strictures were considered steroid-responsive if follow-up
imaging showed normal biliary tree and pancreatic duct,
respectively. Pancreatic mass/enlargement was considered
Table 1: Patient’s demographic and clinical characteristics at the
outbreak of the disease.
Age (mean ± SD) years 47.5 ±14.4 (16–69) years.
Gender (male) 8 (53%)
Family history of autoimmune diseases 3 (20%)
Initial manifestations
Weight loss 13 (87%)
Abdominal pain 9 (60%)
Bile duct stenosis/obstructive jaundice 8 (53%)
Palpebral or periorbital swelling 2 (13%)
Recurrent acute pancreatitis 2 (13%)
Salivary gland swelling/Xerostomy 1 (7%)
Pancreatic focal swelling 1 (7%)
Other autoimmune diseases 2 (13%)∗
Increased serum IgG4 (>135mg/dL) 2/10
Rheumatoid factor 4/8
Positive antinuclear antibodies 6/9
Diabetes mellitus 3/15
Increased IgG 5/10
∗Sj¨ ogren’s syndrome and Graves’ disease.
steroid-responsive if abnormality resolved, with posttherapy
imaging showing normal-appearing pancreas or pancreatic
atrophy. Given the lack of immediate accessibility to serum
IgG4 measurements as a marker of disease, we remained
without this response criterion.
3. Results
Patient’s demographic and clinical characteristics at the out-
break of the disease are shown on Table 1. The mean time
lapse from the onset of symptoms to diagnosis was 42.5
months.
Patientswerefollowedupatourinstitutefor34.9months
(range from 2 to 84 months). Throughout this period,
13 patients reported moderate-to-high intensity abdominal
pain. Four episodes of acute pancreatitis were reported and
four patients were classiﬁed as having chronic pancreatitis.
Moreover, weight loss was documented in 13 patients, with
am e a nl o s so f1 3 .3 ± 6kg. None of the patients had inﬂam-
matory bowel disease.
The median of total IgG was 2400mg/dL (range:
1060mg/dL–4740mg/dL). The two patients with elevated
levels of IgG4 had values of 264mg/dL and 591mg/dL, with
total IgG of 1060mg/dL and 1670mg/dL, respectively, both
within normal values of total IgG.
Additional sites of IgG4+ plasma cell inﬁltration were
histopathologically identiﬁed in 9 patients, some of them
with more than one inﬁltration site: myoﬁbroblastic tumour
(n = 3), lymph node inﬁltration (n = 6), palate (n = 1),
lacrimal gland (n = 1), salival gland (n = 1), gallbladder
(n = 2), prostate (n = 1), orbit (n = 1), liver (n = 1), and
kidney (n = 1).
Nine patients (60%) underwent major abdominal sur-
gery (biliodigestive derivation or Whipple procedure).ISRN Rheumatology 3
3.1. Imaging. Radiological data before treatment were avail-
able for review in 13 patients, for the other 2 cases only writ-
ten radiological reports were analyzed. Twelve patients had
evidence of pancreatic enlargement as previously deﬁned, 3
of this cases were interpreted as having a mass. Pancreatic
duct dilatation was evidenced in 5 cases. In 4 cases, bil-
iary tract dilatation was observed. The most common ex-
trapancreatic involvement identiﬁed was abdominal lym-
phadenopathy in 5/15 cases, followed by interstitial lung
involvement in 4/15 cases, and ﬁnally 3/15 patients had
evidence of glandular involvement on head CT.
3.2. Pathology. Glandular organs, including pancreas, lach-
rymal glands, and minor and major salivary glands, showed
predominantly acinar atrophy and a variable degree of in-
terstitial and periductal inﬂammatory inﬁltrate with abun-
dant plasma cells and ﬁbrosis. Lymph nodes, including
peripancreatic ones, had follicular hyperplasia and dilated
sinuses with abundant plasma cells. All cases met criteria for
LPSP (type 1).
3.3. Response to Treatment. A total of 8 patients were treated
withsteroids.Allofthemreceivedoralprednisoneatdosesof
atleast20mg/qd.Allpatientsrespondedtotreatmentand,to
this day, none has relapsed although this is not yet signiﬁcant
as the follow-up time from the beginning of treatment has
been brief due to delay in diagnosis establishment.
4. Discussion
As was previously mentioned, two main histopathological
variants of autoimmune pancreatitis are currently recog-
nised, and they behave clinically in quite diﬀerent manners.
The recently established International Consensus has sug-
gested the use of this classiﬁcation, but this is not, however,
always feasible due to the need of a suﬃciently large sample
of tissue for a pathologist to study.
In this work, we introduce the ﬁrst series of cases of
autoimmune pancreatitis in the Mexican population, all of
them conﬁrmed by histopathological analysis.
The review of these cases showed that all patients corre-
sponded to the LPSP variant, which is the most frequently
reported, even though our patients’ mean age was much
lower than that expected for this histological type (mean
age of 61.6 versus 47.5 for out population). Nowadays,
it is recognised that one of the most common symptoms
is obstructive jaundice [11]; however, we found it with a
lower frequency than that previously reported, since in Asian
patients the frequency goes from 74 to 88% [12, 13], whereas
only53%ofourpatientshadthissymptomattheonsetofthe
disease. It is worth remarking that we found a relatively high
frequencyofacutepancreatitis,whichinarecentmulticentre
study was mainly associated to IDCP [6]. Abdominal pain
was also reported with a higher frequency than expected
according to previous reports [14].
Extrapancreatic involvement has been mainly associated
to LPSP with, in some cases, 2 to 4 organs aﬀected [15]. This
is congruent with our ﬁndings, as we found 9/15 patients
with multiorgan involvement, although organ involvement
could probably be more common but pass unnoticed for not
making a direct search of it.
It is important to point out that, due to the clinical
presentation of this disease, the diﬀerential diagnosis is es-
tablished mainly with pancreas cancer. In this regard, even
though pancreatic mass was identiﬁed in only 3 patients,
pancreatic growth in the imagining study was found in 12
patients which, in conjunction with the weight loss in the
majority, gave rise to a high rate of surgeries (biliodigestive
derivation or Whipple procedure).
In order to avoid this, one of the main elements that
hint at a diagnosis of autoimmune pancreatitis before the
surgery alternative is the increase in serum IgG4, which has
been found to be high in 75% of patients in some series
[16, 17]. In this concern, there are two important points
in our series: ﬁrstly, IgG4 measurement was requested in
only 10/15 patients, which indicates the low suspicion levels
prevalent with regard to the disease, something that we
hope will change soon; secondly, that only 20% of our pa-
tients showed an increase in serum IgG4 levels, which goes
against what has been reported up to now. There is no
clear explanation for this. The search for cases was based
on histopathological results, and perhaps if a systematic
measurement of IgG4 serum levels in patients suspected of
harboring the disease had taken place, a greater prevalence
of high IgG4 would have been found. Be this as it may,
only a systematic study of this pathology within our ethnic
group can really answer whether these observations are truly
an atypical manifestation. It is also worth mentioning that
Kamisawa et al. [18] recently published the clinical char-
acteristics of patients with IgG4-negative autoimmune pan-
creatitis,inwhichtherewerediﬀerenceswithrespecttothose
patients that showed an increase, and these patients seem
closer to the presentation of our cases.
In conclusion, autoimmune pancreatitis is a disease that
is currently undergoing a process of deﬁnition of its clinical
and diagnostic characteristics. The ﬁrst cases are being found
within our population, and a greater body of evidence is still
being needed in order to establish clearly its presentation
mode. Notwithstanding this, this series results seem to
indicate that, within the Mexican population, patients with
autoimmune pancreatitis with LPSP are aﬀected from the
disease at an earlier age, with a low percentage rate for
high IgG4 serum levels, and with the main symptoms being
abdominal pain, pancreatitis, weight loss, and obstructive
jaundice.
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